More recently this conceptual linking has been extended by associating mutations in SETD1A with disorders that are clinically characterized as NDDs, symptomatically represented with developmental delay, intellectual disability, behavioral problems as well as early onset epilepsy (Yu et al., 2019; Kummeling et al., 2020). Here, SETD1A is linked to epilepsy.